ArticleBeilstein journal of organic chemistry2014
Glycosystems in nanotechnology: Gold glyconanoparticles as carrier for anti-HIV prodrugs.
Article in Beilstein journal of organic chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 79 citations in OpenAlex.
- Nanomedicine in maternal viral infections: advancing prenatal therapies for fetal protection.Discover nano · 2026Review
- Recent Advances in Nanoparticle-Based Antiretroviral Drug Delivery Systems for HIV Treatment and Prevention: A Comprehensive Review.International journal of nanomedicine · 2025Review
- Metal and Metal Oxides Nanoparticles and Nanosystems in Anticancer and Antiviral Theragnostic Agents.Pharmaceutics · 2023Review
- Current Trends and Prospects for Application of Green Synthesized Metal Nanoparticles in Cancer and COVID-19 Therapies.Viruses · 2023Review
- Nano drug-delivery systems for management of AIDS: liposomes, dendrimers, gold and silver nanoparticles.Nanomedicine (London, England) · 2023Review
- Nanotechnology Applications of Flavonoids for Viral Diseases.Pharmaceutics · 2021Review
- Nanotechnology against COVID-19: Immunization, diagnostic and therapeutic studies.Journal of controlled release : official journal of the Controlled Release Society · 2021Review
- Nanotechnology-based approaches for emerging and re-emerging viruses: Special emphasis on COVID-19.Microbial pathogenesis · 2021Review
- Will curcumin nanosystems be the next promising antiviral alternatives in COVID-19 treatment trials?Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Review
- A proposed insight into the anti-viral potential of metallic nanoparticles against novel coronavirus disease-19 (COVID-19).Bulletin of the National Research Centre · 2021Review
- A slow, efficient and safe nanoplatform of tailored ZnS QD-mycophenolic acid conjugates forNanoscale advances · 2020Article
- Gold, Silver, and Palladium Nanoparticles: A Chemical Tool for Biomedical Applications.Frontiers in chemistry · 2020Review
- Advances in Lipid and Metal Nanoparticles for Antimicrobial Peptide Delivery.Pharmaceutics · 2019Review
- Gold nanoparticles in chemo-, immuno-, and combined therapy: review [Invited].Biomedical optics express · 2019Article
- Nanotechnology approaches to eradicating HIV reservoirs.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2019Review
- Reverse Transcriptase Inhibitors Nanosystems Designed for Drug Stability and Controlled Delivery.Pharmaceutics · 2019Review
- The glyconanoparticle as carrier for drug delivery.Drug delivery · 2018Review
- Metal-Based Nanoparticles for the Treatment of Infectious Diseases.Molecules (Basel, Switzerland) · 2017Review
- The role of nanotechnology in the treatment of viral infections.Therapeutic advances in infectious disease · 2017Review
- Role of metal and metal oxide nanoparticles as diagnostic and therapeutic tools for highly prevalent viral infections.Nanomedicine : nanotechnology, biology, and medicine · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The therapeutic approach for the treatment of HIV infection is based on the highly active antiretroviral therapy (HAART), a cocktail of antiretroviral drugs. Notwithstanding HAART has shown different drawbacks like toxic side effects and the emergence of viral multidrug resistance. Nanotechnology offers new tools to improve HIV drug treatment and prevention. In this scenario, gold nanoparticles are an interesting chemical tool to design and prepare smart and efficient drug-delivery systems. Here we describe the preparation and antiviral activity of carbohydrate-coated gold nanoparticles loaded with anti-HIV prodrug candidates. The nucleoside reverse transcriptase inhibitors abacavir and lamivudine have been converted to the corresponding thiol-ending ester derivatives and then conjugated to ~3 nm glucose-coated gold nanoparticles by means of "thiol-for-thiol" ligand place exchange reactions. The drugs-containing glyconanoparticles were characterized and the pH-mediated release of the drug from the nanoparticle has been determined. The antiviral activity was tested by evaluating the replication of NL4-3 HIV in TZM-bl infected cells. The proof-of-principle presented in this work aims to introduce gold glyconanoparticles as a new multifunctional drug-delivery system in the therapy against HIV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.